Chimeric antigen receptor (CAR) T-cell therapies have revolutionised the field of haematological malignancies by achieving impressive remission rates in patients with highly refractory haematological malignancies, improving overall survival. To date, six commercial anti-CD19 and anti-BCMA CAR T-cell products have been approved by the Food and Drug Administration (FDA) for the treatment of relapsed/refractory B-cell haematological malignancies and multiple myeloma. The indications for CAR T-cell therapies are gradually expanding, with these therapies being investigated in a variety of diseases, including non-malignant ones. Despite the great success, there are several challenges surrounding CAR T-cell therapies, such as non-durable responses and high-grade toxicities. In addition, a new safety concern was added by the FDA on 28 November 2023 following reports of T-cell malignancies in patients previously treated with either anti-CD19 or anti-BCMA autologous CAR T-cell therapies both in clinical trials and in the real-world setting. Since then, several reports have been published presenting the incidence and analysing the risks of other secondary malignancies after CAR T-cell therapies. In this opinion article, the current landscape of secondary malignancies after CAR T-cell therapies is presented, along with a proposed strategy for future research aiming at potentially diminishing or abrogating the risk of developing secondary malignancies after CAR T-cell therapies.
25 February 2024 in Human Vaccines & Immunotherapeutics
On Feb 2, 2022, Nature published the paper titled “Decade-long leukemia remissions with the persistence of CD4+ CAR T-cells” (Nature. 2022;602:503–9. doi: 10.1038/s41586-021-04390-6). Accordin
In Western countries, age-related macular degeneration (AMD) is the common cause of central visual loss in the elderly leading to gradual blindness. Studies implicate the retinal pigment epithelium (RPE) as an important player in AMD pathogenesis, as progressive loss of RPE cells and photoreceptors lead to poor visual acuity. Several strategies aim to prevent the RPE degeneration by saving the damaged retinal cells or replacing them. Cell rescue provides retinal cells with trophic or immunomodulatory factors, whereas cell replacement aims to repair and regenerate neuroretina providing new cells. Currently, a major limitation is cell loss from subretinal injections of bolus cell suspensions. The most promising studies focus on tissue transplantation or RPE cell patches hosted on implantable scaffolds made of advanced biomaterials. The latter support the development of artificial 3D retinal constructs improving functional integration capacity and increasing the survival of implanted cells into the damaged retina. However, there is no consensus on the optimal RPE source, delivery strategy, cell dose and animal model for testing. This chapter aims to improve the efficacy of RPE grafting suggesting an optimal cell source, an efficient delivery method, and the topography of retina damage as a determining factor to calculate the effective therapeutic dose.